The New York Times Company (NYSE: NYT) has entered into an agreement to sell its Regional Media Group, consisting of 16 regional newspapers, other print publications and related businesses, to Halifax Media Holdings LLC for $143 million in cash, subject to certain adjustments. The transaction is expected to close within a few weeks and upon completion of the sale, the Company will record an after-tax gain on the sale in the first quarter of 2012. The Company intends to use the net proceeds for general corporate purposes. The Company estimates the net after-tax proceeds from the sale will be approximately $150 million.

“These news organizations have served as trusted institutions in their communities, delivering news and information that matter most to their readers,” said Arthur Sulzberger Jr., chairman of The New York Times Company. “The sale of our Regional Media Group will enable The New York Times Company to continue our transformation to a digitally-focused, multiplatform media company.”

Under the Times Company’s stewardship, the newspapers within the Group have received three Pulitzer Prizes, including the 1971 Prize for editorials in The Gainesville Sun on the peaceful desegregation of Florida’s schools, the 1997 Prize for spot news photography for The Press Democrat for a photograph of a firefighter rescuing a teenager from raging floodwaters and the 2011 Prize for investigative reporting for the Sarasota Herald-Tribune’s year-long series on the challenges that Florida’s property insurance industry have posed for ordinary citizens.

The New York Times Company, a leading media company with 2010 revenues of $2.4 billion, includes The New York Times, the International Herald Tribune, The Boston Globe, 15 other daily newspapers and more than 50 Web sites, including NYTimes.com, BostonGlobe.com, Boston.com and About.com. The Company’s core purpose is to enhance society by creating, collecting and distributing high-quality news, information and entertainment.

More about NYT at www.nytco.com.

*********************

Teva Pharmaceutical Industries Limited (NASDAQ:TEVA) announced that Dr. Rob Koremans, has been appointed President and CEO, Teva Europe and will join the company in March 2012. Dr. Koremans joins Teva after serving as CEO for Zentiva and most recently Senior Vice President Generic Strategy and Development at Sanofi-Aventis.

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, produces, and markets generic drugs; and proprietary branded pharmaceuticals in various therapeutic categories and active pharmaceutical ingredients worldwide.

************************

Cleantech Transit, Inc. (CLNO)

Cleantech Transit, Inc. is in the business of producing and conserving power. Cleantech Transit produces and sells clean electricity globally, with a focus on sustainable energies using renewable resources such as Geothermal, Solar and Wind. Cleantech Transit’s goal is to use innovative technologies to reduce electricity consumption and dependence on carbon based energy. Cleantech Transit, Inc. was founded in 2006 and is based in Scottsdale, Arizona.

Cleantech Transit, Inc. (CLNO) is pleased to announce it has met its funding requirement to secure the Company’s ability to earn in 25% of the 500KW Merced Project.

The Company is in the final stages of closing its initial interest in the Merced Project and is currently working on completing the necessary documentation and expects closing the transaction soon. As previously announced Cleantech has the option to earn up to 40% of the Merced Project and the Company plans to continue to work towards increasing its interest in the Merced Project as they move ahead.

Biomass can be used for fuels, power production, and products that would otherwise be made from fossil fuels. In such scenarios, biomass can provide an array of benefits. For example: The use of biomass energy has the potential to greatly reduce greenhouse gas emissions. Burning biomass releases about the same amount of carbon dioxide as burning fossil fuels. However, fossil fuels release carbon dioxide captured by photosynthesis millions of years ago an essentially “new” greenhouse gas. Biomass, on the other hand, releases carbon dioxide that is largely balanced by the carbon dioxide captured in its own growth (depending how much energy was used to grow, harvest, and process the fuel).

The use of biomass can reduce dependence on foreign oil because biofuels are the only renewable liquid transportation fuels available. Biomass energy supports U.S. agricultural and forest-product industries. The main biomass feedstocks for power are paper mill residue, lumber mill scrap, and municipal waste. For biomass fuels, the most common feedstocks used today are corn grain (for ethanol) and soybeans (for biodiesel). In the near future and with NREL-developed technology agricultural residues such as corn stover (the stalks, leaves, and husks of the plant) and wheat straw will also be used. Long-term plans include growing and using dedicated energy crops, such as fast-growing trees and grasses, and algae. These feedstocks can grow sustainably on land that will not support intensive food crops.

************************

Winner Medical Group Inc. (Nasdaq:WWIN) a leading China -based exporter and retailer of high-quality medical dressings and consumer products made from 100% cotton, announced that BDO China Shu Lun Pan Certified Public Accountants LLP (”BDO China”) has been appointed as the Company’s independent registered public accounting firm to replace BDO Limited (”BDO Hong Kong”).

Winner Medical Group Inc., through its subsidiaries, engages in the research, development, manufacture, and marketing of cotton-base medical dressings and medical disposables.

************************

Abaxis Inc. (Nasdaq:ABAX), a medical products company manufacturing point of care instrumentation and consumables to the medical, research and veterinary markets, announced its Abaxis Veterinary Reference Laboratories (AVRL) Division, based in Olathe, Kansas , is now offering a quantitative antibody test for canine Lyme disease. The new canine Lyme test invented and developed by Abaxis, Inc., measures a combination of antibodies to peptides which mimic certain antigens of the Borrelia burgdorferi spirochete. These antibodies are not found in vaccinated or non-infected patients.

Abaxis, Inc. develops, manufactures, markets, and sells portable blood analysis systems for use in veterinary or human patient-care setting to provide blood constituent measurements for clinicians worldwide.

**************************************************************

**************************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company.Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares of 144 restricted stocks from the company for 12 months of media advertisement and IR services and 4,000,000 shares of 144 restricted stocks from the company for management fee through end of June for Cleantech Transit, Inc. (CLNO.OB).

__

Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) announced that it will host a conference call and live webcast on Wednesday, December 21, 2011 at 8:30 a.m. ET to communicate its 2012 business outlook. A Question & Answer session will follow. In order to participate, please dial the following numbers (at least 10 minutes before the scheduled start time): United States and Canada 866-770-7120; International 1-617-213-8065 and enter passcode 23520783. A live webcast of the call will also be available on Teva’s website at: www.tevapharm.com, under Investor Relations Events and Presentations. Please log in at least 10 minutes prior to the conference call in order to download the applicable audio software.

Teva Pharmaceutidustries Ltd. is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients.

**************************

Majestic Gold Corp. (MJGCF.PK)

Majestic Gold Corp. engages in the exploration and development of mineral properties in China. The company focuses on its gold project located in the prolific gold region of Song Jiagou in eastern Shandong Province. Majestic Gold Corp. is headquartered in Vancouver, Canada.

Gold facts about jewelry include the following. The Ancient Egyptians were the first to use gold to create jewelry. Gold mines produce gold commercially on every continent except Antarctica. Gold is the only precious metal that is yellow in color. Generally, pure gold is too soft and delicate to be used for jewelry, and must be alloyed with other metals to create a metal strong enough to be durable against wear and tear. Gold is the most common and popular precious metal used for wedding rings. Gold is the only known metal that is impervious to rusting.

Majestic Gold Corp. (MJGCF.PK) has arranged a $10,000,000 loan to advance its Song Jiagou project in China. Nine million dollars ($9,000,000) from the proceeds from the loan will be used by the Company to in connection with its Song Jiagou project and the balance of one million dollars ($1,000,000) for general working capital purposes.

The loan will have a one year term and loan principal will be convertible at the option of the lender in whole or in part into common shares (”Shares”) of the Company until twelve months from the date of the loan advance at the price of $0.205 per Share. The loan will bear interest at the rate of 7.5% per annum, payable on maturity, and accrued and unpaid interest will be convertible at the option of the lender in whole or in part into shares of the Company until twelve months from the date of the loan advance at Market Price at the time of conversion.

The lender is at arm’s length from the Company and will not become an insider as a result of any conversion of principal and interest. All shares issued on any conversion of loan principal or interest will be subject to a four month hold period from the date of advance of loan proceeds. The loan is subject to acceptance by the TSX Venture Exchange.

As additional consideration for the loan, the Company has agreed to forward at least $9 million to Majestic Yantai Gold Ltd., a British Virgin Islands company owned 94% by the Company to be used to further advance its Song Jiagou project. The Borrower has also agreed to a 90 day period for reciprocal due diligence reviews and discussions for the possible further involvement of the Lender in the Song Jiagou project.

In the event that no further agreement is reached between the Lender and the Company during the 90 day period, then the loan and a minimum of seven (7) months interest will automatically convert to shares in the Company at a price of $0.205 per share and the interest at Market Price respectively. In addition the Company is pleased to announce that it has arranged a non-brokered private placement of up to 15,000,000 shares to be issued at the price of $0.20 per share for gross proceeds of $3,000,000.

For more information about company: www.majesticgold.net

**************************

Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR) and Astellas Pharma Europe Ltd., a European subsidiary of Tokyo -based Astellas Pharma Inc. announced that the European Commission has granted Marketing Authorization (MA) for DIFICLIR ™ (fidaxomicin) tablets for the treatment of adults with Clostridium difficile infections (CDI) also known as Clostridium difficile-associated diarrhea (CDAD). CDI is a significant problem in hospitals and long-term care facilities all over the world. EMA approval was based on two large, multi-national, Phase 3 clinical trials that demonstrated that DIFICLIR was as effective as oral vancomycin in treating CDI.

Optimer Pharmaceuticals, Inc. is a global biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society.

**************************

Stereotaxis, Inc. (NASDAQ:STXS) announced that the Company has started initial shipments of the Epoch platform, its comprehensive solution for the electrophysiology (EP) lab that is designed to increase efficiency in procedures with a fully-remote, networked robotic and magnetic navigation system. Initial shipments include system upgrades to the new generation Epoch platform from the Niobe® II navigation system for customers in North America and Europe.

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital’s interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias.

**************************************************************

**************************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

Teva Pharmaceutical Industries Limited (Nasdaq:TEVA) announced that it has completed the acquisition of effectively 100% of the outstanding shares of Taiyo Pharmaceutical Industry Co. Ltd. for $934 million in cash. Taiyo is the third largest generics manufacturer in Japan with sales of approximately $530 million in 2010. Taiyo brings to Teva a portfolio of over 550 products and a strong presence in all major channels in the Japanese pharmaceutical market. Teva also gains access to Taiyo’s strong R&D team, local regulatory expertise and a state of the art production facility. Following the acquisition, Teva expects to reach $1 billion in sales in Japan, ahead of its original 2015 target.

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, produces, and markets generic drugs; and proprietary branded pharmaceuticals in various therapeutic categories and active pharmaceutical ingredients worldwide.

********************************************************

Cleantech Transit, Inc. (CLNO)

Cleantech Transit, Inc. is in the business of producing and conserving power. They produce and sell clean electricity globally, with a focus on sustainable energies using renewable resources such as Geothermal, Solar and Wind. Cleantech Transit, Inc goal is to use innovative technologies to reduce electricity consumption and dependence on carbon based energy.

Biomass in the form of fuelwood was perhaps the first energy source used by human beings and was the main fuel till the industrial revolution, after which fossil fuels like coal and oil replaced biomass as the main fuels. Biomass is still an important fuel in developing countries.

Cleantech Transit Inc. was founded to capitalize on technology advances and manufacturing opportunities in the growing clean energy public transportation sector. The Company has expanded its focus to invest directly in specific green projects. Recognizing the many economic and operational advances of converting wood waste into renewable sources of energy, Cleantech has selected to invest in Phoenix Energy (www.phoenixenergy.net). This project could benefit the Company’s manufacturing clients worldwide.

Cleantech Transit, Inc. (CLNO) is pleased to announce it has met its funding requirement to secure the Company’s ability to earn in 25% of the 500KW Merced Project.

The Company is in the final stages of closing its initial interest in the Merced Project and is currently working on completing the necessary documentation and expects closing the transaction soon. As previously announced Cleantech has the option to earn up to 40% of the Merced Project and the Company plans to continue to work towards increasing its interest in the Merced Project as they move ahead.

For more information about Cleantech Transit, Inc. visit its website www.cleantechtransitinc.com

********************************************************

Human Genome Sciences Inc. (Nasdaq:HGSI) announced that it will sponsor a conference call to discuss its financial results for the quarter ended June 30, 2011. These results are expected to be disclosed on Thursday, July 21, 2011, after the capital markets close. The conference call will be hosted by senior management and will be held on Thursday, July 21, 2011 at 4:30 pm Eastern time. Investors may listen to the call by dialing 877-718-5111 or 719-325-4782, passcode 8420907, five to 10 minutes before the start of the call. A replay of the conference call will be available within a few hours after the call ends. Investors may listen to the replay by dialing 888-203-1112 or 719-457-0820, confirmation code 8420907.

Human Genome Sciences, Inc. operates as a biopharmaceutical company. Its principal products in development include BENLYSTA for systemic lupus erythematosus; and raxibacumab for inhalation anthrax.

********************************************************

Kaiser Aluminum Corporation (Nasdaq:KALU) announced that it plans to release its second quarter 2011 financial and operating results on Wednesday, July 27, 2011 after the market closes. The Company will host its quarterly conference call on Thursday, July 28, 2011 at: 10:00 a.m. Pacific, 12:00 p.m. Central & 1:00 p.m. Eastern. The conference call can be directly accessed from the U.S. and Canada at (888-820-9418), internationally at (913-312-0822), or through the Company’s website at http://www.kaiseraluminum.com. An audio archive will be available on the Company’s website following the call.

Kaiser Aluminum Corporation produces and sells semi-fabricated specialty aluminum products primarily in the United States and Canada.

********************************************************

THL Credit, Inc. (Nasdaq:TCRD) announced that it will report its financial results for its fiscal second quarter 2011 after the market closes on August 1, 2011. THL Credit will host a conference call to discuss these results and its business outlook on August 2, 2011, at 8:30 a.m. Eastern Daylight Time. The conference call will be led by James K. Hunt, chief executive officer, and Terrence W. Olson, chief operating officer and chief financial officer.

THL Credit, Inc. is a private equity and mezzanine firm specializing in mature, bridge, PIPES, industry consolidation, acquisition, recapitalization, change of control transactions, and growth capital investments in both sponsored and unsponsored middle-market companies.

**************************************************************

**************************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares of 144 restricted stocks from the company for 12 months of media advertisement and IR services and 4,000,000 shares of 144 restricted stocks from the company for management fee through end of June for Cleantech Transit, Inc. (CLNO.OB).

Cleantech Transit, Inc. (CLNO)

Cleantech Transit, Inc. is in the business of producing and conserving power. They produce and sell clean electricity globally, with a focus on sustainable energies using renewable resources such as Geothermal, Solar and Wind. Cleantech Transit, Inc goal is to use innovative technologies to reduce electricity consumption and dependence on carbon based energy.

Cleantech Transit Inc. was founded to capitalize on technology advances and manufacturing opportunities in the growing clean energy public transportation sector. The Company has expanded its focus to invest directly in specific green projects. Recognizing the many economic and operational advances of converting wood waste into renewable sources of energy, Cleantech has selected to invest in Phoenix Energy (www.phoenixenergy.net). This project could benefit the Company’s manufacturing clients worldwide.

Biomass is a term used mainly in biology. It is a renewable energy source. Biomass is derived from living or recently living organisms. Biomass is carbon based compound. Actually it is consists of carbon, hydrogen, oxygen. Sometimes other atoms may be present in biomass.
The main advantages of biomass are:
1) Biomass is available through out the whole world.
2) Alcohols and other fuels produced by biomass are efficient, viable, and relatively clean-burning
3) When direct combustion of plant mass is not used to generate energy (i.e. fermentation, pyrolysis, etc. are used instead), there is minimal environmental impact
4) Most scientists believe that a wide range of biomass resources are “beneficial” because their use will clearly reduce overall carbon emissions and provide other benefits.
5) This is a fuel source which is inexhaustible theoretically.
6) It is a renewable source of energy
7) Biomass can reduce the Green house gasses relatively. When compared with coal, biomass can reduce sulphar dioxide, nitrogen oxides and other greenhouse gas significantly. Biomass conversion to electricity through co-firing achieves the same rate of efficiency as in a coal-powered plant.

Cleantech Transit Inc., recently announced that funding to be provided to Phoenix Energy for the commercialization of a 500 Kilowatt biomass gasification plant should be eligible to apply for a renewable energy cash back incentive program offered by the U.S. Federal Government. Once the final interconnect process and applications are complete the grant should be received within 60 days. The 5-year grant vesting period, means all parties must remain owner of record for that length of time, underscoring Cleantech and its partners’ commitment to this project and the host community. The U.S. Treasury’s cash grant program was created to provide funding, in lieu of tax credits, for the development of clean energy projects and clean tech jobs nationwide.

The Merced facility has already employed several individuals, both for the construction phase and subsequent plant operations once in service. As Company announced, the full commercial operation of the first plant is expected to be completed during the second quarter of 2011.

For more information about Cleantech Transit, Inc. visit its website www.cleantechtransitinc.com

********************************************

Orofino Gold Corp. (ORFG)

Gold (Symbol Au) a soft, yellow, corrosion-resistant element, the most malleable and ductile metal, occurring in veins and alluvial deposits and recovered by mining or by panning or sluicing. A good thermal and electrical conductor, gold is generally alloyed to increase its strength, and it is used as an international monetary standard, in jewelry, for decoration, and as a plated coating on a wide variety of electrical and mechanical components.

Gold’s aesthetic properties combined with its physical properties have long made it a valuable metal. Throughout history, gold has often been the cause of both conflict and adventure: the destruction of both the Aztec and Inca civilizations, for instance.

Orofino Gold Corp. has several Gold development properties in Colombia, a current hot spot of gold production in the world markets. Orofino Gold Corp. is a Colombia based gold producer founded as a private company in 2009 by former executives with over 50 cumulative years in mining exploration, finance, and development expertise. Orofino’s corporate objective is to continue to build shareholder value through the exploration and development of Senderos de Oro and additional accretive acquisitions, capitalizing on the extensive experience and relationships that management has developed over the past 25 years.

Orofino Gold Corp recently announced results from random chip samples within their Culo Alzado mining area, on the north margin of Senderos de Oro, in Colombia that indicate high grades. A newly recognized gold and silver zone has been discovered in this mining area and the current exploration program will be escalated as recommended by the company’s Qualified Person. A complete listing of Acme Analytical Laboratories reports is available on the Company’s website at www.orofinogoldcorp.com.

Highlights
O Random chip samples returned high grades to 31.80 grams of gold per tonne in average by adopting fusion method (G6Gr).
o Random chip samples returned grades to 66.80 grams of silver per tonne in average by adopting aqua regia digestion method (7AR).

For more information on ORFG please visit www.orofinogoldcorp.com

***************************************************************

Raven Industries Inc. (Nasdaq:RAVN) announced that its board of directors has approved the regular quarterly cash dividend of 18 cents per share, payable July 15, 2011, to shareholders of record on June 30, 2011.

Raven Industries, Inc., together with its subsidiaries, manufactures various products for industrial, agricultural, construction, and military/aerospace markets in the United States and internationally.

***************************************************************

Polycom, Inc. (Nasdaq:PLCM) announced the following upcoming financial community event: Bernstein Strategic Decisions Conference, Date: June 3, 2011, Location: Waldorf Astoria, New York, Time: 06:00 a.m. PT / 09:00 a.m. ET, Presenters: Andy M. Miller, President & CEO / Donald J. Floyd, Vice President. RBC Capital Markets’ Communications Technology Investor Day, Date: June 7, 2011, Location: Boston Harbor Hotel, Boston, Presenters: Susan J. Hayden, EVP, GTM & SMB / Andrew Ashton, Vice President, Finance. William Blair Growth Stock Conference, Date: June 16, 2011, Location: Four Seasons Hotel, Chicago, Time: 08:40 a.m. PT / 11:40 a.m. ET and Presenter: Michael R. Kourey, CFO.

Polycom, Inc. provides communications solutions to enterprise, government, education, and healthcare customers to enable voice, video, and content communications.

***************************************************************

Teva Pharmaceutical Industries Limited (Nasdaq:TEVA) announced that data from studies of two investigational Granulocyte Colony Stimulating Factor (G-CSF) compounds in breast cancer patients receiving myelosuppressive chemotherapy will be presented at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 3-7, 2011. A Phase II/III study of CG-10639, a long-acting recombinant human albumin-human G-CSF to prevent chemotherapy-induced neutropenia, demonstrated similar outcomes to pegfilgrastim (PEGF), for both efficacy and safety measures in breast cancer patients. The primary endpoint was duration of severe neutropenia (DSN) in days during cycle one of treatment. These data showed the non-inferiority of CG-10639 (40mg and 50mg) to PEGF; a confirmatory Phase III study comparing CG-10639 40mg and PEGF 6mg is currently underway. No clinically relevant immunogenicity with CG-10639 was observed.

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, produces, and markets generic drugs in various therapeutic categories worldwide.

**************************************************************

**************************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (CRWE.OB) anticipates receiving 5,000,000 shares of 144 restricted stocks from the company for 12 months of media advertisement and IR services for Cleantech Transit, Inc. (CLNO.OB).
Crown Equity Holdings Inc. (CRWE.OB) has previously received 500,000 shares of (144) restricted common stock and 500,000 shares of free trading shares from a third party (QU CUI You) for six months of advertisement services (which has expired) for Orofino Gold Corp. (PINK SHEETS:ORFG).

PDL BioPharma Inc. (NASDAQ:PDLI) increased 3.75% to close at $5.81. PDLI traded 5.76 million shares for the day and its earning per share remained $0.85. PDL BioPharma, Inc. engages in the management of antibody humanization patents and royalty assets, which consist of Queen et al. patents and license agreements with various biotechnology and pharmaceutical companies. Its Queen et al. patents primarily cover humanized antibodies, methods for humanizing antibodies, polynucleotide encoding in humanized antibodies, and methods of producing humanized antibodies. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.

Amgen, Inc. (NASDAQ:AMGN) decreased 1.00% to close at $51.39. AMGN traded 5.44 million shares for the day and its earning per share remained $4.79. Amgen Inc., a biotechnology medicines company, discovers, develops, manufactures, and delivers human therapeutics based on advances in cellular and molecular biology primarily in the United States, Europe, and Canada. The company markets primarily recombinant protein therapeutics in supportive cancer care, nephrology, and inflammation. Its principal products include Aranesp and EPOGEN erythropoietic-stimulating agents that stimulate the production of red blood cells.

Teva Pharmaceutical Industries Ltd (ADR) (NASDAQ:TEVA) increased 1.78% to close at $50.82. TEVA traded 4.79 million shares for the day and its earning per share remained $3.66. Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, produces, and markets generic drugs in various therapeutic categories worldwide. It offers generic pharmaceutical products in a range of dosage forms, such as tablets, capsules, ointments, creams, liquids, injectables, and inhalants. The company also provides branded products, including Copaxone to treat multiple sclerosis; and Azilect to treat Parkinson’s disease. The company was founded in 1901 and is headquartered in Petach Tikva, Israel.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.